{{Rsnum
|rsid=12714145
|Gene=GGCX
|Chromosome=2
|position=85560218
|Orientation=plus
|GMAF=0.4109
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GGCX
}}{{PMID Auto
|PMID=20694283
|Title=Gamma-glutamyl carboxylase and its influence on warfarin dose
|OA=1
}}

{{PharmGKB
|RSID=rs12714145
|Name_s=GGCZ, intron 2 C/T
|Gene_s=GGCX
|Feature=
|Evidence=PubMed ID:19794411
|Annotation=Risk or phenotype-associated allele: undetermined. Phenotype: The variant allele was not associated with warfarin maintenance dose variability (p = 0.7669). Study size: 283. Study population/ethnicity: Hospitalized Caucasian patients aged 75 years or older, recruited Sep 2002-Nov 2004 in Ivry, France, and Oct 2005-Mar 2008 from 14 French centers. Significance metric(s): not significant. Type of association: GN; PK.
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165111652
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=18574025
|Title=The largest prospective warfarin-treated cohort supports genetic forecasting.
|OA=1
}}

{{PMID Auto
|PMID=18680736
|Title=Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
}}

{{PMID Auto
|PMID=22158446
|Title=Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12714145
|overall_frequency_n=44
|overall_frequency_d=126
|overall_frequency=0.349206
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}